Quizzes & Puzzles46 mins ago
Has The Oxford Vaccine Be Hyped?
Astra/Zeneca’s share price has plummeted on fears that the vaccine will not be licensed for use in the USA.
Investors are doubting the results.
AZ originally claimed 70% effectiveness. That was bumped up to 90% on the results from two doses. But that turns out to have been done by error. A more clinical test of Brazilians only gave a 62% result.
There was criticism that the trial did not test on any older people, anyone over 55 was excluded.
62% is still impressive, but a third less than the other two. Have we been slightly misled?
https:/ /www.th eguardi an.com/ world/2 020/nov /26/scr utiny-g rows-ov er-oxfo rd-univ ersitya strazen eca-vac cine
Investors are doubting the results.
AZ originally claimed 70% effectiveness. That was bumped up to 90% on the results from two doses. But that turns out to have been done by error. A more clinical test of Brazilians only gave a 62% result.
There was criticism that the trial did not test on any older people, anyone over 55 was excluded.
62% is still impressive, but a third less than the other two. Have we been slightly misled?
https:/
Answers
It's entirely appropriate to scrutinise the results, although it's worth noting that *all* drug companies so far have only announced preliminary vaccine studies. It's more important to back a vaccine that works than a vaccine that's made here. Given the choice, I want to see the Astra/Zeneca one working, not least because it will be the cheapest, offered...
19:50 Thu 26th Nov 2020
It seems to be US regulators and business analysts who are sceptical of the rigour of the Oxford trials.
Maybe I am being niave. Maybe the US Government wants to pay far more for a US vaccine than a much cheaper one. That might be true, but by not disclosing a dosing error and instead presenting it as a benefit seems disingenuous. Whatever, it seems to have cast doubt and confusion that only the most blinkered and bigoted anti-foreigner is happy to dismiss.
Maybe I am being niave. Maybe the US Government wants to pay far more for a US vaccine than a much cheaper one. That might be true, but by not disclosing a dosing error and instead presenting it as a benefit seems disingenuous. Whatever, it seems to have cast doubt and confusion that only the most blinkered and bigoted anti-foreigner is happy to dismiss.
TCL
No they didn’t disclose the half dose/Full dose was a mistake and due to a manufacturing error.
Normally in a trial, that compromised data would not have been included. But it had unexpectedly good results so they couldn’t resist mixing the two results. Except the one giving 90% effectiveness was trialed on people who were young and not high risk.
No they didn’t disclose the half dose/Full dose was a mistake and due to a manufacturing error.
Normally in a trial, that compromised data would not have been included. But it had unexpectedly good results so they couldn’t resist mixing the two results. Except the one giving 90% effectiveness was trialed on people who were young and not high risk.
From the BBC website,
"Some of the shots were weaker than they were designed to be, containing much less of the ingredient that is meant to give a person immunity.
The jab is actually two shots, with the second given a month after the first as a booster.
While most of the volunteers in the trial got the correct dose for both of their two shots, some didn't.
Regulators were told about the error early on and they agreed that the trial could continue and more volunteers could be immunised.
The error had no effect on vaccine safety."
As the Regulators knew about the error At the time and it was also reported by the media, what is the problem?
"Some of the shots were weaker than they were designed to be, containing much less of the ingredient that is meant to give a person immunity.
The jab is actually two shots, with the second given a month after the first as a booster.
While most of the volunteers in the trial got the correct dose for both of their two shots, some didn't.
Regulators were told about the error early on and they agreed that the trial could continue and more volunteers could be immunised.
The error had no effect on vaccine safety."
As the Regulators knew about the error At the time and it was also reported by the media, what is the problem?
Related Questions
Sorry, we can't find any related questions. Try using the search bar at the top of the page to search for some keywords, or choose a topic and submit your own question.